Physician profile
Michael Patrick Bowen
NPI 1558771410
$3,245.29
in general payments reported to CMS, 2019-2025
11 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,343 · 2023: $1,398 · 2024: $335 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Travel and Lodging: $683 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.11 |
| Travel and Lodging | $682.88 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,938.62 | 2022-2023 | Inspire |
| Jazz Pharmaceuticals INC. | $749.22 | 2022-2024 | |
| Abbvie INC. | $117.96 | 2023-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.51 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $95.22 | 2024-2025 | Trintellix |
| Lundbeck LLC | $92.88 | 2023-2024 | Rexulti |
| Harmony Biosciences LLC | $66.79 | 2022-2024 | Wakix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.40 | 2025 | Rejoyn |
| Janssen Pharmaceuticals, INC | $21.27 | 2025 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $15.32 | 2022 | |
| Neuronetics, INC. | $13.10 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.